Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.
Jesus G. Berdeja, MD, director of Myeloma Research at Sarah Cannon Research Institute, discusses the findings from the phase 2 results of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study (NCT03548207).
Researchers were gratified by the results seen in this study, says Berdeja, especially in regard to the response rates. The objective response rate was 97% with 57% of patients achieving a stringent complete response and 92% a partial response or better.
According to Berdeja, the median progression-free survival had not been reached yet, but at 12-months, 76.6% of patients remained in remission in the study.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More